arct-032
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2023 (NCT05712538)
Timeline
Indications
Studied for
Mechanism of action
- Cystic fibrosis transmembrane conductance regulatorSupplementation
CFTR supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06747858 | Phase 2 | Dec 12, 2024 | Arcturus Therapeutics |
| NCT05712538 | Phase 1 | Feb 15, 2023 | Arcturus Therapeutics, Novotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arcturus Therapeutics | For profit | 2 | 2 | 2 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1